Research and Developments

Page 1 of 2212345...1020...Last »

September 16, 2018

Second Trial Showing Efficacy for Stem Cell Treatment of Dry AMD

Posted in: Latest News, Research and Developments

A second trial begun in 2018 is showing positive results with replacing defective cells leading to vision loss from dry (geographic) macular degeneration. Implanted cells derived from stem cells have been implanted into five patients by researchers from University of Southern California (USC) and the University of California, Santa Barbara. Results at one year have
read more »

September 6, 2018

Gout Associated With Increased Risk of AMD

Posted in: Latest News, Research and Developments

A recent study by researchers at the University of Alabama at Birmingham School of Medicine, has looked into the association between age-related macular degeneration (AMD) and gout. Gout is a form of arthritis resulting from inflammation in the joints caused by the build-up of uric acid crystals and is associated with oxidative stress. The main
read more »

September 2, 2018

Novel Gene Therapy for Wet AMD Approved For Trials

Posted in: Latest News, Research and Developments

Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD. “We are excited
read more »

August 19, 2018

What Are The Highest Priorities in AMD Research?

Posted in: Latest News, Research and Developments

Four eye health stakeholder groups have come together to help define the focus of research in age-related macular degeneration (AMD). Their purpose was to prioritize clinical questions important for researchers to answer when developing clinical practice guidelines and identifying treatment outcomes important to patients. Participants in the initiative were: American Academy of Ophthalmology (AAO) Retina/Vitreous
read more »

August 18, 2018

12 Weeks Between Injections: Good News for Wet AMD patients

Posted in: Latest News, Research and Developments

Regeneron Pharmaceuticals has announced that the FDA has approved extending the dosage regimen of EYLEA, its proprietary drug for treatment of wet macular degeneration (AMD).The decision was based on second-year data from the Phase 3 VIEW 1 and 2 trials in which patients were treated with doses given at least every 12 weeks plus additional
read more »

August 18, 2018

Mifepristone Still Showing Positive Results for Treatment of Central Serous Chorioretinopathy

Posted in: Latest News, Research and Developments

For the past 18 years, reports have been published here on the slow progress of research for treatment of central serous chorioretinopathy (CSC). Sometimes misdiagnosed as early-onset age-related macular degeneration, CSC is a disease of the central retina (the macula) affecting mostly middle-aged males, and it is thought to be caused by over-production of stress
read more »

July 26, 2018

New Port Delivery System Unveiled for Wet AMD Treatment

Posted in: Latest News, Research and Developments

Genentech has announced positive, top line results from a Phase 2 study of its Port Delivery System (PDS) with Lucentis in people with wet age-related macular degeneration (AMD). The small, refillable eye implant, which is slightly longer than a grain of rice, is designed to allow people with wet AMD to go several months without
read more »

July 20, 2018

Abicipar for Wet AMD May Extend Time Between Treatments

Posted in: Latest News, Research and Developments

Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages.
read more »

July 19, 2018

Emixustat Found Ineffective

Posted in: Latest News, Research and Developments

The drug Emixustat has been in Phase 1/2 trials since 2008 for treatment of dry macular degeneration. Disappointingly, the drug has now been found to be ineffective at reducing the growth rates of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Preclinical analysis of Emixustat indicated that it inhibited the activity of the
read more »

May 19, 2018

Summary of Research and Development — 2018

Posted in: Health and Nutrition, Latest News, Research and Developments, Therapies, Treatments, and Procedures

Transcript of a presentation to the International Low Vision Support Group June 2018 Dan Roberts, Director Select this link for audio-visual format INTRODUCTION This is our 13th annual summary of leading research and developments occuring during the past 12 months in the fields of blindness and low vision. Sources for further information will appear beneath
read more »

Page 1 of 2212345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann